BCDA News and Press, BioCardia Inc.

Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into f...

A look at the top 10 most actives in the United States Inotiv Inc. (NOTV) rose 91.8% to $0.1661 on volume of 1,034,019,819 shares Direxion Daily Semiconductor Bear 3X (SOXS) rose 31.5% to $6.84 on volume of 925,373,286 shares Direxion Small Cap Bear 3X (TZA) rose 10.6% to $4.7 on volume of ...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X (SOXS) rose 16.3% to $6.05 on volume of 160,614,179 shares SmartKem Inc. (SMTK) rose 59.2% to $0.5095 on volume of 159,303,757 shares Real Messenger Corporation (RMSG) rose 170.5% to $2.975 on volume...

2026-06-05 09:28:37 ET Denver, Colorado ( www.247marketnews.com ) – Investors continue to focus on companies capable of generating meaningful clinical milestones, regulatory achievements, and commercial opportunities in large underserved markets. Several small-cap healthcare name...

SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biol...

SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical D...

– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development – Novel therapeutic approach ...

SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc.  [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase. ...

2026-05-18 09:00:22 ET Image source: The Motley Fool. May 15, 2026, 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-15 18:21:28 ET More on BioCardia BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript BioCardia, Inc. 2025 Q4 - Results - Earnings Call Presentation BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript BioCardia GAAP EPS of -$0.21 misses by $0.0...